Ixekizumab treatment of patients with moderate-to-severe plaque psoriasis.

ABSTRACT: Objectives: To asses skin clearance and patient-reported outcomes for ixekizumab treatment. Methods: IXORA-R enrolled adults with moderate-to-severe plaque psoriasis, defined as static Physician’s Global Assessment ≥ 3, PASI ≥ 12 and involved body surface area ≥ 10%. The trial was registered with ClinicalTrials.gov (NCT03573323).

ORGANISM(S): Homo sapiens

PROVIDER: GSE178228 | GEO | 2023/04/10

REPOSITORIES: GEO